Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | CASP6 | P55212 | 1/20 | 0.33 |
| ▸ | TYMS | P04818 | 1/20 | 0.32 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.32 |
| ▸ | PDE7B | Q9NP56 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | PMM2 | O15305 | 1/20 | 0.31 |
| ▸ | MPI | P34949 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16739101 | 1.00 | VCP (0.40) | VCPALDH1A1HIF1AVCAM1TDP1 | |
| SCHEMBL25411924 | 0.87 | ALDH1A1 (0.37) | VCPALDH1A1HIF1ATDP1ATM | |
| SCHEMBL26908251 | 0.83 | VCP (0.40) | VCPALDH1A1HIF1AVCAM1TDP1 | |
| SCHEMBL1340438 | 0.82 | ALDH1A1 (0.43) | ALDH1A1HIF1AVCAM1TDP1ATM | |
| SCHEMBL29860351 | 0.82 | ALDH1A1 (0.43) | ALDH1A1HIF1AVCAM1TDP1ATM | |
| SCHEMBL239430 | 0.80 | MEN1 (0.41) | ALDH1A1TDP1TSHRMAPTTYMS | |
| SCHEMBL6227151 | 0.80 | VCP (0.38) | VCPALDH1A1HIF1AVCAM1TDP1 | |
| SCHEMBL2463690 | 0.80 | GRIN2D (0.41) | VCPALDH1A1HIF1AVCAM1TDP1 | |
| SCHEMBL20797684 | 0.80 | PTGER4 (0.48) | VCPALDH1A1HIF1AVCAM1TDP1 | |
| SCHEMBL20471631 | 0.80 | ALDH1A1 (0.33) | VCPALDH1A1TDP1MAPTPTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094958-A | PARP1 inhibitors and uses thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122059929-A | Quinoxaline derivatives as anticancer agents | 阿斯利康(瑞典)有限公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-122036687-A | Quinoxaline derivatives as anticancer agents | 阿斯利康(瑞典)有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-122036686-A | Quinoxaline derivatives as anticancer agents | 阿斯利康(瑞典)有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-122010903-A | Quinoxaline derivatives as anticancer agents | 阿斯利康(瑞典)有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4655073-A2 | CEREBLON-BASED KRAS DEGRADING PROTACS ANS USES RELATED THERETO | Arvinas Operations, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| EP-4613752-A1 | POLYCYCLIC POLY(ADP-RIBOSE) POLYMERASE SELECTIVE INHIBITOR | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2025-09-10 | — | — | EP | disclosed |
| US-20250270224-A1 | POLYCYCLIC POLY(ADP-RIBOSE) POLYMERASE SELECTIVE INHIBITOR | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2025-08-28 | — | — | US | disclosed |
| CN-120092010-A | Polycyclic poly (ADP-ribose) polymerase selective inhibitors | 轩竹生物科技股份有限公司 | 2025-06-03 | — | — | CN | disclosed |
| WO-2025096856-A1 | COVALENT CEREBLON LIGANDS | C4 THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-116964037-A | Diaminotriazine compounds | 巴斯夫欧洲公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-116891456-A | Heterocyclic derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-10-17 | — | — | CN | disclosed |
| CN-116867758-A | IRAK degradation agents and uses thereof | 凯麦拉医疗公司 | 2023-10-10 | — | — | CN | disclosed |
| WO-2023118085-A1 | METHODS OF TREATING BRAIN TUMOURS AND NEUROBLASTOMAS | ASTRAZENECA AB (SE) | 2023-06-29 | — | — | WO | disclosed |
| EP-4172152-A1 | QUINOXALINE DERIVATIVES AS ANTI-CANCER DRUGS | Astrazeneca AB (SE) | 2023-05-03 | — | — | EP | disclosed |
| CN-115768760-A | Quinoxaline derivatives as anti-cancer agents | 阿斯利康(瑞典)有限公司 | 2023-03-07 | — | — | CN | disclosed |
| CN-114981267-A | MKK4 inhibitor 3-benzoyl-1H-pyrrolo [2,3-B ] pyridine derivatives for the treatment of liver diseases | 海帕瑞吉尼克斯股份有限公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-109734674-B | Aniline WDR5 protein-protein interaction inhibitor and preparation method and application thereof | 中国药科大学 | 2022-08-26 | — | — | CN | disclosed |
| WO-2022161801-A1 | DIAMINOTRIAZINE COMPOUNDS | BASF SE (DE) | 2022-08-04 | — | — | WO | disclosed |
| EP-3288931-B2 | CERTAIN PROTEIN KINASE INHIBITOR | CHONGQING FOCHON PHARMACEUTICAL CO LTD (CN) | 2022-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270224-A1 | POLYCYCLIC POLY(ADP-RIBOSE) POLYMERASE SELECTIVE INHIBITOR | PARP1, PARP11, PARP2 | VCP 2979/4885ALDH1A1 1101/4885HIF1A 3172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.